Median Technologies: A Dual-Engine Strategy for AI-Driven Cancer Diagnosis

SOPHIA ANTIPOLIS, France – July 22, 2026 – After years of development and clinical validation, Median Technologies is making a decisive pivot from prototype to profit. The French health tech firm has secured critical regulatory approvals in the U.S. and Europe for its flagship AI-powered lung cancer screening software, eyonis® LCS. Bolstered by a recent €50 million capital increase and a record-setting order book in its established imaging services division, the company is now executing a deliberate commercial rollout that offers a compelling case study in bringing sophisticated medical AI to market.

"The first half of 2026 has been transformational for Median Technologies," said Fredrik Brag, CEO and Founder, in a recent announcement. He highlighted the strengthened cash position, solid performance of the company's iCRO (imaging contract research organization) business, and the major regulatory milestones for eyonis® LCS. "Median has entered a new phase of its development. Our priority is to continue executing our commercialization strategy for eyonis® LCS while building on the strong foundations of our iCRO business."

This move signals a crucial transition for the company and the broader AI-in-oncology ecosystem, shifting focus from algorithmic potential to the complex realities of market access, physician adoption, and revenue generation.

A Fortified Foundation for Commercial Launch

Bringing a novel Software as a Medical Device (SaMD) to the global market is a capital-intensive endeavor, and Median has strategically fortified its balance sheet for the road ahead. The successful completion of an upsized €50 million capital increase in June provides the financial firepower needed for a multi-year commercial push. As of June 30, 2026, the company reported cash and cash equivalents of €60.8 million.

This infusion extends Median's cash runway well into the first half of 2028, a critical buffer that allows for strategic investment in sales infrastructure, marketing, and customer support. Furthermore, with outstanding warrants that could inject an additional €44.3 million upon exercise, the runway could potentially stretch into 2029. This long-term financial visibility is a significant advantage in a competitive field where many AI startups operate with much shorter financial horizons.

"What's compelling about Median's position is the de-risking of its commercial strategy," commented one health tech analyst. "The iCRO business provides a stable, profitable foundation. That gives them the resources and time to be patient and methodical with the eyonis® rollout, a luxury many pure-play AI ventures simply don't have."

The Dual-Engine: iCRO Stability Fuels SaMD Ambition

Median's unique strength lies in its dual-engine business model. While eyonis® represents the high-growth future, the company's iCRO division serves as its reliable and profitable present. This division, which provides AI-based image analysis services for oncology drug developers, remains the company's sole source of revenue for now and has demonstrated remarkable momentum.

For the first half of 2026, iCRO revenue grew 4.4% year-over-year to €11.8 million. More significantly, the order backlog—a key indicator of future revenue—reached an all-time high of €82.4 million, up 15.6% from the previous year. This record backlog is fueled by its status as a preferred imaging provider for some of the world's largest pharmaceutical companies and its expansion into the fast-growing East Asian clinical trial markets.

This isn't just a separate, successful business; it's a synergistic one. The iCRO division's "Imaging Lab" leverages advanced AI, differentiating its services and acting as a real-world showcase of Median's technological prowess. The vast amounts of imaging data and deep relationships with oncology leaders cultivated through the iCRO business provide invaluable insights and a potential commercial launchpad for the eyonis® portfolio.

Unlocking Global Markets with Clinically Proven AI

The true catalyst for Median's new chapter is eyonis® LCS. The first half of 2026 saw the culmination of five years of investment as the software secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) in February, followed by CE marking under the stringent European Medical Device Regulation (MDR) in July. These approvals unlock the world's two largest and most mature markets for lung cancer screening.

Positioned in a global AI lung screening market projected to exceed $700 million by 2034, eyonis® LCS enters as a highly differentiated product. It is the first FDA-cleared AI device for the combined detection and diagnosis of lung cancer nodules in screening programs. Clinical data highlights its power: manufacturer-reported studies show it can reduce false positives by 68% and false negatives by 66% compared to unaided radiologists. With a sensitivity of 93.3% and specificity of 92.4%, it promises to enhance accuracy and workflow efficiency.

"The primary challenge in lung screening isn't just finding nodules; it's confidently deciding which ones warrant invasive follow-up," noted a radiologist not affiliated with the company. "A tool that dramatically reduces the false positive rate, as eyonis® claims, could be a game-changer for our workflow, for reducing healthcare costs, and for alleviating patient anxiety."

Executing a Multi-Channel Go-to-Market Strategy

With regulatory gates open and funding secured, the focus shifts to execution. Median is launching eyonis® LCS with a primary focus on the United States, which has a well-established screening ecosystem and favorable reimbursement environment.

Under its U.S. subsidiary, eyonis Inc., the company has been building a dedicated team with expertise in commercial sales, clinical application support, and technical deployment. The strategy is not to go it alone but to leverage a multi-channel approach. A key early win is a strategic commercial partnership with Tempus AI, a leader in AI-powered precision medicine. This agreement provides access to Tempus's extensive network and data-driven platform, accelerating market penetration. Median has stated that advanced discussions with other industry partners are ongoing.

Looking beyond the immediate launch, the company is already advancing its product pipeline. Programs for detecting incidental pulmonary nodules (IPN) and diagnosing hepatocellular carcinoma (HCC), the most common type of liver cancer, are under development. This demonstrates a clear ambition to build the eyonis® brand into a comprehensive portfolio of AI-powered tools for early cancer diagnosis, translating the initial success in lung cancer into a broader platform for future growth.